
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is projected to experience robust growth driven by anticipated increases in procedure volumes in the atrial fibrillation (AF) market, with estimates suggesting a 20-30% rise in left atrial appendage closure (LAAC) volumes due to expanded indications and broader adoption. The global AFib market is expected to grow from $9 billion to $15 billion by 2028, representing a significant compound annual growth rate (CAGR), alongside a projected 15% CAGR for the total electrophysiology (EP) market. With positive trial results and innovations in catheter technologies, Boston Scientific is well-positioned to capture substantial market share, as evidenced by survey respondents projecting approximately 18% incremental increases in procedure volumes following successful clinical trial outcomes.
Bears say
The financial outlook for Boston Scientific is negatively impacted by several key factors, including a projected decline in the company's market share for RF and cryoablation products, which are expected to fall significantly, indicating a loss of competitiveness in these segments. Additionally, concerns over slower-than-anticipated adoption of the company's portfolio, particularly related to recent acquisitions, alongside limited operating leverage and increasing debt levels, suggest an unfavorable financial trajectory. Furthermore, the company faces heightened risks from competitive product launches, potential delays in new product approvals, and pricing pressures in its CRM and DES portfolios, which are crucial to its overall revenue.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares